Enhancing involvement of people with multiple sclerosis in clinical trial design.
Emma GrayAnneesa AmjadJenny RobertsonJudy BeveridgeSusan ScottGuy PeryerMarie BraisherCheryl PughSara PeresKathryn C FitzgeraldMaria Pia SormaniJeremy ChatawayPublished in: Multiple sclerosis (Houndmills, Basingstoke, England) (2023)
Active, meaningful PPI in clinical trial design increases the quality and relevance of studies and the likelihood of impact for the patient community. We offer recommendations for enhancing PPI in future MS clinical trials.